Login / Signup

Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.

Christina M EckhardtMatthew J CummingsKartik N RajagopalanSarah BordenZachary C BitanAllison WolfAlex KantorThomas BrieseBenjamin J MeyerSamuel D JacobsonDawn ScottoNischay MishraNeena M PhilipBrie A StotlerJoseph SchwartzBeth ShazSteven L SpitalnikAndrew EisenbergerEldad A HodJessica JustmanKen CheungW Ian LipkinMax R O'Donnell
Published in: Trials (2020)
ClinicalTrials.gov: NCT04359810 Date of trial registration: April 24, 2020 Retrospectively registered FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Keyphrases
  • sars cov
  • randomized controlled trial
  • coronavirus disease
  • endothelial cells
  • study protocol
  • respiratory syndrome coronavirus
  • clinical trial
  • phase iii
  • induced pluripotent stem cells
  • phase ii
  • pluripotent stem cells